The incidence of suicide is on the rise, and some have even termed it a public health crisis. On March 5 the Food and Drug Administration approved a new nasal spray medication for treatment resistant depression. The nasal spray, Spravato (esketamine) is a form of the well-known and widely used anesthetic ketamine. Ketamine was found to be an effective antidepressant in the 1990’s when researchers at Yale discovered these effects. These findings were confirmed by researchers who published their finding in the Journal of American Medical Association in 2006.
